Matija Snuderl
Assistant Professor (Clinical) of Pathology
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (15)
Supplementary Table 1 includes the metadata on all subjects, including basic demographics and medical history. Supplementary Table 2 provides statistics on chrom 8 gene expression among tumors with H3K27me3 loss. Note: no changes have been made to this file since our last resubmission.
Year:
2025
SOX2 is a core pluripotency factor in human embryonic stem cells (hESCs), but upon differentiation to the three germ layers, its expression is preserved selectively in neuroectoderm. The mechanisms regulating SOX2 transcription in distinct developmental stages remain incompletely understood. Here, we demonstrate that a distant enhancer 550 kb from the human SOX2 locus is selectively activated in neural stem cells (NSCs) and establishes long-range contact with the SOX2 gene. CRISPR-Cas9 excision of the enhancer has no effect in hESCs but reduces SOX2 transcription in NSCs and impairs neuroectodermal differentiation and forebrain specification in teratomas and cerebral organoids. CRISPR excision of a CTCF recognition motif adjacent to the enhancer does not affect enhancer activation in neuroectoderm but reduces chromatin looping and SOX2 transcription to partially reproduce phenotypes seen with enhancer deletion. Our findings indicate that the development of the human nervous system depends on a developmentally regulated long-range contact between a distant enhancer and the SOX2 locus.
Year:
2025
Purpose: Noninvasive prognostic biomarkers to inform clinical decision-making are an urgent unmet need for the management of patients with glioblastoma (GBM). We previously showed that higher circulating cell-free DNA (ccfDNA) concentration is associated with worse survival in GBM. However, the biology underlying this is unknown. Experimental Design: We prospectively enrolled 129 patients with treatment-naïve GBM with blood drawn prior to initial resection (baseline) and at the time of the first postradiotherapy MRI. We performed ccfDNA methylation deconvolution to determine cellular sources of ccfDNA. ELISA was performed to detect citrullinated histone 3 (citH3), a marker of neutrophil extracellular traps (NET). Multiplex proteomic analysis was used to measure soluble inflammatory proteins. Results: We found that neutrophils contributed the highest proportion of prognostic ccfDNA. The percentage of ccfDNA derived from neutrophils was correlated with total [ccfDNA] but only in patients receiving preoperative corticosteroids. At baseline and on therapy, [citH3] was significantly higher in the plasma of patients with GBM receiving corticosteroids compared with corticosteroid-naïve GBM or no-cancer controls. Unsupervised hierarchical clustering of ccfDNA methylation patterns yielded two clusters, with one enriched for patients with the NETosis phenotype and who received corticosteroids. Unsupervised clustering of circulating inflammatory proteins yielded similar results. Conclusions: These data suggest neutrophil-mediated NETosis is the dominant source of prognostic ccfDNA in patients with GBM and may be associated with glucocorticoid exposure. If further studies show that pharmacological inhibition of NETosis can mitigate the deleterious effects of corticosteroids, these plasma markers will have important clinical utility as noninvasive correlative biomarkers.
Year:
2025
Supplemental Figure 1. Patients and assays Supplemental Figure 2. Survival analysis at baseline and post-radiation Supplemental Figure 3. Correlative analysis of all ccfDNA deconvolution subsets with [ccfDNA]. Supplemental Figure 4. Analysis of % neutrophil tissue DNA and pre-operative steroids. Supplemental Figure 5. Correlative analysis of all ccfDNA deconvolution subsets with [citH3]. Supplemental Figure 6. Analysis of % neutrophil tissue DNA and [citH3]. Supplemental Figure 7. Analysis of [citH3], pre-operative steroid dose, and tumor volume. Supplemental Figure 8. Analysis of % neutrophil ccfDNA by steroid exposure. Supplemental Figure 9. Percent neutrophil ccfDNA and [citH3] at time of first post-radiation MRI. Supplemental Figure 10. Analysis of % neutrophil ccfDNA and total [ccfDNA] by steroid exposure. Supplemental Figure 11. Molecular sub-type analysis of Clusters 1 and 2 from plasma ccfDNA differential methylation results. Supplemental Figure 12. Unsupervised clustering of tissue DNA methylation data, differential methylation, and pathway analysis. Supplemental Figure 13. Analysis of Clusters 1 and 2 from tissue DNA differential methylation analysis. Supplemental Figure 14. Analysis of Clusters 1 and 2 from plasma ccfDNA differential methylation results.
Year:
2025
List of all methylGSA results for (Gene Ontology,GO, gene sets) with differential methylation comparing patients in cluster 1 vs cluster 2 from unsupervised clustering of the tissue DNA methylation results.
Year:
2025
Standard techniques for detecting genomic rearrangements in formalin-fixed paraffin-embedded (FFPE) biopsies have important limitations. We performed FFPE-compatible Hi-C on 44 clinical biopsies comprising large B-cell lymphomas (n=18), plasma cell neoplasms (n=14), and other diverse lymphoid cancers, identifying consistent topological differences between malignant B cell and plasma cell states. Hi-C detected expected oncogene rearrangements at high concordance with fluorescence in-situ hybridization (FISH) and supported enhancer-hijacking in recurrent rearrangements of BCL2 , CCND1 , and MYC , plus unanticipated variants involving homologous loci. Hi-C identified unanticipated non-coding rearrangements involving PD-1 ligand genes and other loci of potential therapeutic relevance, distinguished between functionally divergent classes of BCL6 rearrangements, and provided topological information supporting the interpretation of atypical MYC rearrangements. In biopsies lacking MYC -activating rearrangements, Hi-C revealed differential interactions with functionally-validated disease-specific native MYC locus enhancers. FFPE-compatible Hi-C detects oncogene rearrangements and their topological consequences at genome-wide scale, finding clinically-relevant drivers that are missed by standard approaches.
Year:
2025
Brain tumors affect about 1 million people in the U.S., with aggressive types like glioblastoma having very low survival rates due to complex tumor biology and the protective blood-brain barrier. Current treatments are limited in effectiveness, and our understanding of brain tumor biology remains incomplete. High dimensional multiplexed imaging has enabled us to better understand the tumor microenvironment (TME); however, analyses typically rely on cell segmentation, which is error-prone, may discard useful context outside the cell boundary, and neglects complex tissue-wide features. To address this limitation, we developed a segmentation-free, self-supervised representation learning framework that enables us to train directly on multiplexed images using masked image modeling. We used this approach to analyze 389 imaging mass cytometry images from 185 brain tumor patients. To study tissue-wide features, we first trained our model on 64×64 micron tiles capturing neighborhoods of 10-20 cells, which we termed local tumor microenvironments (LTMEs). To further characterize these LTMEs, we trained our model on 16×16 micron tiles centered on individual cells in our dataset, so that each tile captures a single cell and its surrounding area, which we termed single-cell microenvironments (SCMEs). This multi-scale, self-supervised approach enables a detailed analysis of the heterogeneity within the brain TME, examining single cells in their spatial context. In addition to validating known findings, we identified a novel LTME in GBM patients, composed primarily of tumor cells and a few B and T cells, which strongly correlated with increased survival. By analyzing these B cells with our SCME model, we found they were distinct from other GBM B cells, and higher concentrations of these B cells were linked to improved survival. In conclusion, our study introduces a multi-scale, segmentation-free, self-supervised machine learning model that provides unprecedented insights into brain TMEs, enabling discovery of previously unrecognized cell interactions and spatial features that are predictive of patient survival.
Year:
2025
Background Intracerebral schwannomas are rare tumors resembling their peripheral nerve sheath counterparts but localized in the central nervous system (CNS). They are not classified as a separate tumor type in the 2021 World Health Organization classification. This study aimed to compile and characterize these rare neoplasms morphologically and molecularly. Methods We analyzed 20 tumor samples by histology, RNA next-generation sequencing, DNA-methylation profiling, copy number analyses, and single-nucleus RNA sequencing (snRNA-seq). Clinical data, including age, sex, and disease progression, were collected. Magnetic resonance imaging (MRI) series were included when available. Results All cases with tissue available for histology review (n = 13) were morphologically consistent with intracerebral schwannoma, but differed in their extent of glial fibrillary acidic protein staining. All (n = 20) shared DNA-methylation profiles distinct from other CNS tumors, as well as from Vestigial-like family (VGLL)-altered peripheral nerve sheath tumors. Most cases (n = 14/17) harbored fusions of either Vestigial-like family member 3 (VGLL3) or Vestigial-like Family member 1 (VGLL1) (CHD7::VGLL3 [n = 9/17] and EWSR1::VGLL1 [n = 5/17]). In 2 cases, the presence of a VGLL3 fusion was also confirmed by copy number analyses (n = 2/17). MRI (n = 4) showed well-defined, nodular tumors with strong, homogeneous enhancement and no diffusion restriction. Tumors were located throughout the neuroaxis (supratentorial [n = 15], infratentorial [n = 4], and spinal [n = 1]). snRNA-seq of a VGLL1-fused tumor indicated VGLL1 upregulation in 28.6% of tumor cells (n = 1). During a median follow-up of 1.8 years (range 3 months-9 years), none of the tumors recurred (n = 10). Conclusions We identify and define a new benign tumor class, designated VGLL-altered intraparenchymal CNS schwannomas. These tumors feature VGLL alterations and a specific DNA-methylation profile, with schwannoma-like histopathology and CNS localization, akin to previously classified intracerebral schwannomas.
Year:
2024
Purpose: DNA methylation profiling stratifies isocitrate dehydrogenase ( IDH )-mutant astrocytomas into methylation low- and high-grade groups. We investigated the utility of the T2-fluid-attenuated inversion recovery (T2-FLAIR) mismatch sign for predicting DNA methylation grade and cyclin-dependent kinase inhibitor 2A/B ( CDKN2A/B ) homozygous deletion, a molecular biomarker for grade 4 IDH -mutant astrocytomas, according to the 2021 World Health Organization classification. Experimental Design: Preoperative MRI scans of IDH -mutant astrocytomas subclassified by DNA methylation profiling ( n = 71) were independently evaluated by two radiologists for the T2-FLAIR mismatch sign. The diagnostic utility of T2-FLAIR mismatch in predicting methylation grade, CDKN2A/B status, copy number variation, and survival was analyzed. Results: The T2-FLAIR mismatch sign was present in 21 of 45 (46.7%) methylation low-grade and 1 of 26 (3.9%) methylation high-grade cases ( P CDKN2A/B status ( P = 0.028) with 87.5% specificity, 86.4% positive predictive value, and 42.9% negative predictive value. Overall multivariable Cox analysis showed that retained CDKN2A/B status remained significant for progression-free survival ( P = 0.01). Multivariable Cox analysis of the histologic grade 3 subset, which was nearly evenly divided by CDKN2A/B status, copy number variation, and methylation grade, showed trends toward significance for DNA methylation grade with overall survival ( P = 0.045) and CDKN2A/B status with progression-free survival ( P = 0.052). Conclusions: The T2-FLAIR mismatch sign is highly specific for low methylation grade and intact CDKN2A/B in IDH -mutant astrocytomas.
Year:
2024
Purpose: DNA methylation profiling stratifies isocitrate dehydrogenase ( IDH )-mutant astrocytomas into methylation low- and high-grade groups. We investigated the utility of the T2-fluid-attenuated inversion recovery (T2-FLAIR) mismatch sign for predicting DNA methylation grade and cyclin-dependent kinase inhibitor 2A/B ( CDKN2A/B ) homozygous deletion, a molecular biomarker for grade 4 IDH -mutant astrocytomas, according to the 2021 World Health Organization classification. Experimental Design: Preoperative MRI scans of IDH -mutant astrocytomas subclassified by DNA methylation profiling ( n = 71) were independently evaluated by two radiologists for the T2-FLAIR mismatch sign. The diagnostic utility of T2-FLAIR mismatch in predicting methylation grade, CDKN2A/B status, copy number variation, and survival was analyzed. Results: The T2-FLAIR mismatch sign was present in 21 of 45 (46.7%) methylation low-grade and 1 of 26 (3.9%) methylation high-grade cases ( P CDKN2A/B status ( P = 0.028) with 87.5% specificity, 86.4% positive predictive value, and 42.9% negative predictive value. Overall multivariable Cox analysis showed that retained CDKN2A/B status remained significant for progression-free survival ( P = 0.01). Multivariable Cox analysis of the histologic grade 3 subset, which was nearly evenly divided by CDKN2A/B status, copy number variation, and methylation grade, showed trends toward significance for DNA methylation grade with overall survival ( P = 0.045) and CDKN2A/B status with progression-free survival ( P = 0.052). Conclusions: The T2-FLAIR mismatch sign is highly specific for low methylation grade and intact CDKN2A/B in IDH -mutant astrocytomas.
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Collaborators (51)
Richard E. Phillips
University of Pennsylvania
Simon Paine
University of Nottingham
Dennis Shasha
New York University
Ali Nabavizadeh
University of Pennsylvania
Raymond H. Kim
Associate Professor
University Health Network
Noah Brown
Assistant Professor
University of Michigan Hospital
Minji Kim
Assistant Professor
University of Michigan
Matthew Lee
Clinical Assistant Professor
NYU Langone Health
Russell Taylor Sundby
Assistant Professor
Thomas Jefferson University
Brendan C. Dickson
-
Yiying Yang
NYU Langone Health
Aristotelis Tsirigos
Associate Professor (Research) of Pathology
NYU School of Medicine
Russell J.H. Ryan
Associate Professor
University of Michigan Medical School
Erica L. Carpenter
University of Pennsylvania
Peter Park
Harvard University
Manoj Bhasin
Director, Genomics, Proteomics, Bioinformatics and Single cell Biology
Children's Healthcare of Atlanta
Jimin Tan
Assistant Professor
NYU School of Medicine
Adrienne M Flanagan
Professor of Musculoskeletal Pathology
-
Christine Stadelmann
-
George Jour
Associate professor
NYU Langone Medical Center
Justin Jordan
University of Texas Southwestern Medical Center
Wanding Zhou
Assistant Professor
Children's Hospital of Philadelphia
Jeffrey Szymanski
Assistant Professor
Mayo Clinic Minnesota
Jeffrey Wisoff
Professor of Neurosurgery and Pediatrics
NYU School of Medicine
Tejus Bale
Assistant Attending L1
Memorial Sloan Kettering Cancer Center
Eveline Teresa Hidalgo
NYU Langone Health
Martin Hasselblatt
University Hospital Münster
Sylvia Kurz
Associate Professor
Yale University Yale Cancer Center
David Viskochil
Professor
University of Utah
Sebastian Brandner
University College London
Arie Perry
University of California, San Francisco
Donald M. O'Rourke
Professor
University of Pennsylvania
Jeffrey Allen
Otto and Marguerite Manley and Making Headway Foundation Professor of Pediatric Neuro-Oncology and Professor (Clinical) of Neurology
NYU School of Medicine
Rajan Jain
Professor
NYU Langone Health
Nicholas Seewald
Assistant Professor
University of Pennsylvania
david harter
NYU Langone Medical Center
Angela C. Hirbe
Washington University School of Medicine
Erik Sulman
Chair
Duke University
Zev Binder
Research Assistant Professor
University of Pennsylvania
Kandace Gollomp
Assistant Professor
Children's Hospital of Philadelphia
Nischalan Pillay
Professor
University College London
Daniel Orringer
Associate Professor
NYU Langone Health
Felix Sahm
University Hospital Heidelberg
Kevin Jones
Professor
University of Utah
Isidro Cortes Ciriano
Research Group Leader
European Bioinformatics Institute
Benjamin Liechty
Assistant Professor of Pathology and Laboratory Medicine
Weill Cornell Medicine
Yoshihiro Nishida
Nagoya University Hospital
Marilyn Bui
Senior Member and Professor
H Lee Moffitt Cancer Center and Research Institute
Dimitris Placantonakis
Professor
NYU Langone Medical Center
Stephen J Bagley
University of Pennsylvania
Sharon L Gardner
Associate Professor (Clinical) of Pediatrics
NYU School of Medicine
Make your next move.
Prepare your application
Review drafts before you send them.